



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)
文檔簡介
Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEAmifostinethioldihydrochlorideCat.No.:HY-103640CASNo.:14653-77-1Synonyms:WR-1065dihydrochloride分?式:C?H??Cl?N?S分?量:207.16作?靶點:MDM-2/p53作?通路:Apoptosis儲存?式:-20°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed
storage,awayfrommoisture)溶解性數(shù)據(jù)體外實驗H2O:≥100mg/mL(482.72mM)DMSO:25mg/mL(120.68mM;Needultrasonic)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲備液1mM4.8272mL24.1359mL48.2719mL5mM0.9654mL4.8272mL9.6544mL10mM0.4827mL2.4136mL4.8272mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;?旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限:-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲存時,請在6個?內(nèi)使?,-20°C儲存時,請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液,再依次添加助溶劑:(為保證實驗結(jié)果的可靠性,澄的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實驗的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶)1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥1.67mg/mL(8.06mM);Clearsolution2.請依序添加每種溶劑:10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥1.67mg/mL(8.06mM);Clearsolution3.請依序添加每種溶劑:10%DMSO>>90%cornoilSolubility:≥1.67mg/mL(8.06mM);ClearsolutionBIOLOGICALACTIVITY?物活性Amifostinethiol(WR-1065)dihydrochloride可以保護正常組織免受某些癌癥藥物的毒性作?,并通過JNK依賴性信號通路激活p53。IC50&Targetp53[1]體外研究TheDNA-bindingactivityisincreasedinaAmifostinethioldihydrochloride(Amifostinethiol)concentration-dependentmanner.Cellstreatedwith1mMAmifostinethioldihydrochloridefor24hrevealthatallofthep53-inducedgenesanalyzedaretransactivatedfollowingAmifostinethioldihydrochloridetreatment,inap53-dependentmanner.Significantly,treatmentwithAmifostinethioldihydrochlorideleadstoa3-foldincreaseinluciferaseexpressiondrivenbyAP-1,anda5-foldincreasewhenthisreportergeneisdrivenbyNF-κB,whenthesevaluesarenormalizedtothelevelofthecotransfectedβ-galactosidasegene[2].體內(nèi)研究TheresultsshowthatAmifostinethioldihydrochloride(Amifostinethiol)attenuatestheseverityof6-OHDA-inducedcatalepsy(P[3].PROTOCOLKinaseAssay[2]ForWesternanalysis,cellsaretreatedwith1mMWR-1065dihydrochloride(WR-1065)for24h,andsubconfluentculturesofcellsareharvestedandlysedinRIPAbuffersupplementedwithproteaseinhibitors.Proteinconcentrationsaredeterminedbyadetergent-compatibleassay.WesternblotsareblockedandincubatedinantibodyinPBS/0.2%Tween20/5%nonfatdrymilk.Blotsareincubatedwith1μg/mLantibodyfor1hatroomtemperature,followedbywashinginPBS/0.2%Tween20andincubationinperoxidase-conjugatedsecondaryantibodyandchemiluminescencedetection[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.CellAssay[2]TotesttheeffectsofpaclitaxelinthepresenceorabsenceofWR-1065dihydrochloride(WR-1065)oncellgrowth,cellsareseededin96-welltissueculturedishesat20%confluenceandallowedtoattachandrecoverforatleast24h.Varyingcombinationsofpaclitaxelaloneorincombinationwitha60minpretreatmentwith1mMWR-1065dihydrochloridearethenaddedtoeachwell,andtheplatesareincubatedforanadditional48hor72h.Thenumberofsurvivingcellsisdeterminedbystaining.Thepercentageofcellskilledbypaclitaxeland/orWR-1065dihydrochlorideiscalculatedasthepercentagedecreaseinsulforhodamineBbindingcomparewithcontrolcells[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEAnimalSeventytworatsaredividedrandomlyinto9equalgroups:1)ControlgroupreceivesnoinjectionandisleftAdministration[3]untreatedfortheentireperiodoftheexperimentasintactanimals;2)Shamoperatedgroupissubjectedonlytosurgicalprocedure;3)Vehicle(saline)-treatedgroupreceives2μLsaline(intra-SNc);4)Lesionedgroupreceives6-hydroxydopamine;5)Vehicle+6OHDAgroupreceivessalineasavehicle3daysoncedaily(2μL/rat)before6-OHDAinjection;6to8)Ratsinthesegroupsarepretreatedwithintra-SNcinjectionofWR-1065dihydrochloride(WR-1065)(20,40and80μg/2μL/rat)3daysbefore6-OHDAinjection;9)Non-lesionedanimalsreceiveintra-SNcinjectionofWR-1065dihydrochloride(80μg/2μL/rat)forthreedays[3].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?FrontCellDevBiol.2020Jul29;8:703.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].PluquetO,etal.ThecytoprotectiveaminothiolWR1065activatesp53throughanon-genotoxicsignalingpathwayinvolvingc-JunN-terminalkinase.JBiolChem.2003Apr4;278(14):11879-87.[2].ShenH,etal.BindingoftheaminothiolWR-1065totranscriptionfactorsinfluencescellularresponsetoanticancerdrugs.JPharmacolExpTher.2001Jun;297(3):1067-73.[3].AfshinKheradmand,etal.EffectofWR-1065on6-hydroxydopamine-inducedcatalepsyandIL-6level
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 綠色能源技術(shù)研發(fā)合作合同
- 醫(yī)療器械代理注冊合同書
- 正式借款合同
- 城市綠化項目實施與驗收合同
- 節(jié)電小貼士(教學(xué)設(shè)計)-2023-2024學(xué)年四年級下冊綜合實踐活動滬科黔科版
- 第21課《莊子二則-北冥有魚》教學(xué)設(shè)計 2023-2024學(xué)年統(tǒng)編版語文八年級下冊
- 社區(qū)團購倉儲租賃協(xié)議
- 第5課計算機的資源管理 教學(xué)設(shè)計
- 律師事務(wù)所勞動仲裁合同8篇
- 無產(chǎn)權(quán)房屋買賣合同范本5篇
- 工程結(jié)構(gòu)質(zhì)量特色介紹
- 超全六年級陰影部分的面積(詳細答案)
- 提高護士對搶救藥品知曉率PDCA案例精編版
- 八字萬能速查表(有圖)
- 清華大學(xué)MBA課程——運籌學(xué)
- 架橋機安全教育培訓(xùn)試卷及答案(共3頁)
- 濕法冶金浸出凈化和沉積PPT課件
- 通信桿路工程施工
- 初中物理光學(xué)經(jīng)典題(共23頁)
- 化學(xué)反應(yīng)工程流固相非催化反應(yīng)PPT課件
- 二次回路和電纜編號原則
評論
0/150
提交評論